Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2016 - 2026)

Lineage Cell Therapeutics has reported Income from Non-Controlling Interests over the past 17 years, most recently at $23000.0 for Q1 2026.

  • For Q1 2026, Income from Non-Controlling Interests rose 675.0% year-over-year to $23000.0; the TTM value through Mar 2026 reached $193000.0, up 394.87%, while the annual FY2025 figure was $166000.0, 514.81% up from the prior year.
  • Income from Non-Controlling Interests for Q1 2026 was $23000.0 at Lineage Cell Therapeutics, down from $41000.0 in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at $100000.0 in Q2 2025 and troughed at -$48000.0 in Q3 2023.
  • A 5-year average of $8411.8 and a median of -$4000.0 in 2025 define the central range for Income from Non-Controlling Interests.
  • Biggest five-year swings in Income from Non-Controlling Interests: plummeted 433.33% in 2023 and later skyrocketed 869.23% in 2025.
  • Year by year, Income from Non-Controlling Interests stood at -$8000.0 in 2022, then soared by 862.5% to $61000.0 in 2023, then tumbled by 62.3% to $23000.0 in 2024, then soared by 78.26% to $41000.0 in 2025, then crashed by 43.9% to $23000.0 in 2026.
  • Business Quant data shows Income from Non-Controlling Interests for LCTX at $23000.0 in Q1 2026, $41000.0 in Q4 2025, and $29000.0 in Q3 2025.